Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Age-related macular degeneration ... Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST, President Oh Sang-Rok) has developed a new therapeutic agent ...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

However, the drug manufacturer did not present any ... aflibercept for the treatment of neovascular (wet) age-related macular degeneration, shows that there is another way. In the TALON study ...